纳米抗体应用于肿瘤治疗的研究现状  

Current status of research on application of nanobodies in tumor therapy

作　　者：王志明[1] 杨立霞[1] WANG Zhi-ming;YANG Li-xia(NCPC New Drug Research and Development Co., Ltd. State Key Laboratory of Antibody Drug Development, Shijiazhuang 050015, Hebei Province, China)

机构地区：[1]华北制药集团新药研究开发有限责任公司抗体药物研制国家重点实验室,河北石家庄050015

出　　处：《中国生物制品学杂志》2018年第4期431-436,共6页Chinese Journal of Biologicals

基　　金：国家"重大新药创制"科技重大专项(2014ZX09201041);河北省科技计划项目(16272401D)

摘　　要：纳米抗体(nanobodies,Nbs)具有较小的相对分子质量,其独特的分子结构使其适用于疾病诊断治疗等诸多领域,由于其缺少Fc段,不能引发普通单抗药物在肿瘤治疗中重要的细胞毒作用,在肿瘤治疗领域的前景一度不被看好,但随着药物研究的不断深入及更合理的设计,Nbs在该领域的应用正在不断扩展。目前研发中的Nbs是以直接拮抗作用、与效应分子相连、与药物递送系统相连等多种形式参与肿瘤治疗,并可联合应用于靶向性放射核素疗法及光动力疗法中。本文就Nbs的成药特性、Nbs在肿瘤治疗中的应用及目前处于临床试验阶段Nbs药物的研究现状作一综述。Given the unique molecular characteristics,nanobodies（Nbs）with low molecular mass are amenable to many applicability as diagnostic or therapeutic tools.When nanobodies were used in oncology,not much was expected from them initially because the lackof Fc-effector domain needed for cytotoxicity.However,the deepening research and clever rational design may overcome this limitation.The Nbs in research and development participate in tumor therapy in a variety of forms：direct antagonistic effects,linkage to effector moieties,incorporation into drug delivery systems,and application to radionuclide therapy and photodynamic therapy,etc.This paper reviews the drug characteristics and application if Nbs in tumor therapy as well as current status of research on Nbs drugs in clinical trial.

关 键 词：纳米抗体 肿瘤 

分 类 号：R73-362[医药卫生—肿瘤]